Gene-based medicines

Transforming the lives of patients                            with serious diseases

Corporate Presentation

OVERVIEW

Stock Information


Oct 21, 2020 8:40 PM EDT
Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

Oct 21, 2020

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

Oct 07, 2020

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

Sep 29, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 22, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease

View All

Upcoming Events & Recent Presentations

There are currently no events scheduled.
Oct 2020
Phase 1 CARBON Top-Line Data Presentation
Oct 2020
CRISPR Therapeutics Corporate Presentation
Jun 2020
2020 AACR II Virtual Meeting Poster: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors
Jun 2020
2020 AACR II Virtual Meeting Poster: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro
Jun 2020
2020 AACR II Virtual Meeting Poster: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors
Jun 2020
2020 AACR II Virtual Meeting Poster: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells
Jun 2020
2020 European Hematology Association (EHA) Congress Presentation
May 2020
2020 ASGCT Annual Meeting Poster: Multiplexing of up to 10 gene edits using CRISPR/Cas9 generate CAR-T cells with improved function
May 2020
2020 ASGCT Annual Meeting Poster: Dual Guide CRISPR/Cas9 Editing of the CCR5 Gene Provides Complete Protection Against HIV in Humanized Mouse Models
May 2020
2020 ASGCT Annual Meeting Poster: Insertion of Short Double-Stranded Oligonucleotides Using CRISPR/Cas9 as a Therapeutic Approach for Glycogen Storage Disease Type 1a
Nov 2019
CRISPR Therapeutics Data Update Call Presentation
Nov 2019
2019 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells
Sep 2019
2019 European Association for the Study of Diabetes (EASD) Presentation
May 2019
2019 ASGCT Annual Meeting Poster: CRISPR/Cas9 Gene Editing to Produce Multiple Allogeneic CAR-T Cell Candidates Showing Consistently High Potency, Durability, Lack of Alloreactivity, and Ability to Overcome Immune Suppression
Apr 2019
2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells
Apr 2019
2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR/Cas9 Gene-edited CAR-T Cells Targeting CD33 Show Potent Preclinical Activity Against AML Cells
Dec 2018
2018 Annual Meeting of The American Society of Hematology (ASH) Poster: Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA
Nov 2018
2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function
May 2018
2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
Apr 2018
2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells
Apr 2018
2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen

View All